AstraZeneca PLC (AZN) Stock Analysis
AstraZeneca PLC (AZN) is a multinational biopharmaceutical company focused on discovering, developing, and commercializing prescription medicines across oncology, cardiovascular, respiratory, and immunology. Investors research AZN to evaluate its diversified drug portfolio, pipeline strength, and valuation relative to peers in the pharmaceutical sector.
Get a full AI research report on AZN
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does AstraZeneca PLC do?
AstraZeneca generates revenue by developing and selling branded prescription medications across six therapeutic areas: oncology (including Tagrisso, Imfinzi, Lynparza, and Enhertu), cardiovascular (Brilinta, Farxiga), respiratory and immunology (Symbicort, Fasenra, Tezspire), renal and metabolism (Crestor, XIGDUO XR), vaccines and immune (Beyfortus, Synagis), and specialty care (Soliris, Ultomiris). The company operates a global commercial infrastructure to market these products and invests heavily in R&D to advance its pipeline of late-stage candidates.
Bull case
- ✓Forward P/E of 14.46 suggests the stock trades at a discount to its trailing P/E of 25.77, indicating market expectations for earnings growth in coming years.
- ✓PEG ratio of 1.17 implies the company's valuation is reasonable relative to its expected growth rate, a metric favored by growth-focused investors.
- ✓Strong gross margin of 81.69% and operating margin of 23.46% demonstrate pricing power and operational efficiency in a competitive pharmaceutical market.
- ✓Return on equity of 21.97% indicates the company generates substantial profit from shareholder capital, outperforming many large-cap peers.
- ✓Diversified oncology portfolio (Tagrisso, Imfinzi, Lynparza, Enhertu) and respiratory franchise (Symbicort, Fasenra, Tezspire) provide multiple revenue streams and reduce single-product risk.
Bear case
- ✗Debt-to-equity ratio of 64.23% is elevated, indicating the company carries significant financial leverage that could constrain flexibility during downturns or limit capital allocation options.
- ✗Current ratio of 0.886 and quick ratio of 0.664 fall below the 1.0 threshold, suggesting potential near-term liquidity constraints and reliance on operational cash flow.
- ✗Trailing P/E of 25.77 remains elevated in absolute terms, leaving limited margin of safety if earnings growth disappoints or market sentiment shifts.
- ✗Pharmaceutical companies face ongoing patent cliff risks as blockbuster drugs lose exclusivity; AstraZeneca's future growth depends on pipeline success and market adoption of newer medicines.
- ✗Regulatory and pricing pressures in major markets (U.S., Europe) could compress margins or limit revenue growth for existing and new products.
AZN valuation & financial health
AstraZeneca trades at a trailing P/E of 25.77 with a forward P/E of 14.46, suggesting the market prices in meaningful earnings growth ahead. The PEG ratio of 1.17 indicates the valuation is not excessive relative to expected growth. Profitability metrics are solid: net margin of 17.02%, operating margin of 23.46%, and ROE of 21.97% reflect a well-managed, profitable business. However, the balance sheet shows leverage concerns—debt-to-equity of 64.23% and a current ratio of 0.886 indicate the company relies on operational cash generation and may have limited financial flexibility. The 1.92% dividend yield and 46.95% payout ratio suggest modest shareholder distributions with room for reinvestment in R&D.
The bottom line
AstraZeneca presents a mixed financial profile: strong profitability and reasonable forward valuation metrics are offset by elevated leverage and tight near-term liquidity. Key factors to weigh include the company's ability to drive earnings growth through pipeline advancement and market adoption of newer oncology and respiratory products, the trajectory of patent expirations on legacy drugs, and the sustainability of pricing in regulated markets. Investors should monitor quarterly pipeline progress, debt reduction initiatives, and competitive dynamics in key therapeutic areas to assess whether forward earnings estimates justify the current valuation.
Frequently asked questions
What does AstraZeneca PLC do?
AstraZeneca is a biopharmaceutical company that discovers, develops, manufactures, and sells prescription medicines across oncology, cardiovascular, respiratory, immunology, vaccines, and specialty care. It operates globally and generates revenue through branded drug sales in these therapeutic areas.
Is AZN overvalued or undervalued?
The trailing P/E of 25.77 is elevated, but the forward P/E of 14.46 and PEG ratio of 1.17 suggest the market is pricing in future earnings growth. Valuation assessment depends on confidence in the company's pipeline and ability to achieve those growth expectations.
What are AstraZeneca's main revenue drivers?
Key revenue drivers include oncology medicines (Tagrisso, Imfinzi, Lynparza, Enhertu), respiratory products (Symbicort, Fasenra, Tezspire), cardiovascular drugs (Brilinta, Farxiga), and specialty care therapies (Soliris, Ultomiris). The company's growth depends on market adoption of newer products and pipeline advancement.
What are the main risks for AZN investors?
Key risks include high financial leverage (debt-to-equity of 64.23%), tight liquidity (current ratio of 0.886), patent expirations on legacy drugs, regulatory and pricing pressures in major markets, and pipeline execution risk. Competitive intensity in oncology and respiratory markets also poses a threat.
How profitable is AstraZeneca?
AstraZeneca is highly profitable with a net margin of 17.02%, operating margin of 23.46%, and gross margin of 81.69%. Return on equity of 21.97% indicates efficient use of shareholder capital, though high leverage affects overall financial health.
Does AstraZeneca pay a dividend?
Yes, AstraZeneca pays a dividend with a yield of 1.92% and a payout ratio of 46.95%, indicating the company distributes less than half of earnings to shareholders while retaining capital for R&D and debt management.
Research AZN with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.